Skip to main content

Dr. Devasmita C. Dev, M. D.

Nephrology (Kidney) (Nephrology Physician)

At a glance

In the NPI registry since
2006

Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    TX license K5900 (first issued 1998; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Payments from drug and device companies

In 2025, 1 companies reported 4 payments worth $13.06 in total to this clinician.

By type
Education$13.06

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 14, 2025Travere Therapeutics, Inc.
Jan 14, 2025
Education
Filspari · Kidney Disease · in-kind
$4.15
Jan 14, 2025Travere Therapeutics, Inc.
Jan 14, 2025
Education
Filspari · Kidney Disease · in-kind
$4.15
May 5, 2025Travere Therapeutics, Inc.
May 5, 2025
Education
Filspari · Kidney Disease · in-kind
$2.38
May 5, 2025Travere Therapeutics, Inc.
May 5, 2025
Education
Filspari · Kidney Disease · in-kind
$2.38

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Virginia →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,250 in research payments for these studies, mostly to the institutions running them.

  • A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Salem

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 10, 2014), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1881708071. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.